← Back
Data updated: Mar 10, 2026
Biogen
BIIB NeurologyImmunologyRespiratory
Neuroscience-focused biotech with MS portfolio (Tecfidera, Tysabri) and controversial Alzheimer's drug Leqembi. Pioneer in neurological diseases.
$9.8B
Revenue (2024)
$22.0B
Market Cap
-
Trials
12
Approved (2yr)
Key Drugs
Recent Activity
TYSABRI 2025-03-18
Labeling
TOFIDENCE 2025-03-06
Labeling
SKYCLARYS 2024-12-20
Efficacy
SKYCLARYS 2024-12-20
Labeling
TOFIDENCE 2024-12-03
Labeling
VUMERITY 2024-09-11
Manufacturing (CMC)
ZURZUVAE 2024-07-31
Labeling
TOFIDENCE 2024-07-22
SPINRAZA 2024-04-10
Labeling
SPINRAZA 2024-04-10
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Neurology 71%
2 drugs Phase 3: 18 Phase 2: 14 Phase 1: 20
Immunology 15%
1 drugs Phase 3: 4 Phase 2: 2 Phase 1: 1
Respiratory 5%
0 drugs Phase 3: 2 Phase 2: 1
Cardiovascular 4%
0 drugs Phase 3: 2
Oncology 4%
0 drugs Phase 3: 1 Phase 1: 4
Pipeline Strength Pro
Loading...
Competitors Pro
Novartis big-pharma
Oncology, Cardiovascular, Immunology, Respiratory
GSK big-pharma
Respiratory, Oncology, Immunology, Neurology
Roche big-pharma
Oncology, Neurology, Immunology, Respiratory
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Immunology
Boehringer Ingelheim big-pharma
Oncology, Respiratory, Immunology, Cardiovascular